MedTrace Logo

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D

NCT06948760 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-03-25

No results posted yet for this study

Summary

A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)

Conditions

Interventions

DEVICE

Control-IQ insulin pump with Lyumjev insulin

Control-IQ insulin pump with insulin using settings determined by experimental conversion factor

DEVICE

Control-IQ insulin pump with Humalog or Novolog

Control-IQ insulin pump with Humalog or Novolog using optimized insulin settings

Sponsors & Collaborators

  • University of Virginia

    collaborator OTHER

  • Mark D. DeBoer, MD, MSc., MCR

    lead OTHER

Principal Investigators

  • Mark DeBoer, MD · University of Virginia Center for Diabetes Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-23
Primary Completion
2026-02-27
Completion
2026-03-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06948760 on ClinicalTrials.gov